These results revealed that PBRM1 inhibition could promote the infiltration of M1 macrophages into RCC, thereby improving the efficacy of anti‐PD‐1 immunotherapy and prolonging the survival of tumor‐bearing mice. This evidence concerns the gene PDCD1 and neoplasm.